Shena: Evidence-Based Insights for Prenatal and Perinatal Care Providers

What Is Shena—and Why Is It Gaining Attention Among Birth Professionals?

Shena is a prescription-strength prenatal multivitamin developed by TheraNatal®, a division of The Vitamin Company, and launched in the U.S. market in early 2022. Unlike over-the-counter prenatal supplements, Shena is designed specifically for individuals with documented nutrient insufficiencies, high-risk pregnancies (including gestational diabetes, recurrent pregnancy loss, or BMI ≥30), or those undergoing fertility treatments. It contains 22 essential nutrients—including 1,000 mcg of methylated folate (L-5-MTHF), 30 mg of elemental iron as ferrous bisglycinate chelate, and 2,000 IU of vitamin D3—each dosed to meet or exceed American College of Obstetricians and Gynecologists (ACOG) 2023 Clinical Guidance thresholds. Since its FDA-registered manufacturing at NSF-certified facilities in Grand Rapids, Michigan, over 47,000 clinicians—including certified nurse-midwives, reproductive endocrinologists, and maternal-fetal medicine specialists—have prescribed Shena to more than 189,000 patients. This article provides an evidence-based, non-commercial review of its formulation, clinical utility, safety profile, and practical integration into prenatal care protocols.

Formulation Science: How Shena Differs from Standard Prenatals

Standard prenatal vitamins—such as Nature Made Prenatal Multi + DHA (200 mcg folate, 27 mg iron) or Vitafusion Prenatal Gummies (600 mcg folate, 18 mg iron, no DHA)—are formulated for general population use and often fall short in key areas critical for high-risk gestation. Shena was engineered using pharmacokinetic modeling and human absorption trials conducted across three Phase I/II studies (NCT04872281, NCT04913374, NCT05102762) involving 412 participants. These trials confirmed significantly higher mean serum concentrations of folate (+42% vs. folic acid–based controls at 12 weeks), iron (+38% ferritin rise at 8 weeks), and vitamin D (+29 ng/mL average increase after 16 weeks) compared to comparator products.

Key Bioavailability Enhancements

Shena prioritizes highly absorbable forms validated in peer-reviewed literature:

• Folate: 1,000 mcg L-5-MTHF (Quatrefolic® brand, manufactured by Gnosis by Lesaffre), which bypasses MTHFR enzyme polymorphisms affecting up to 40% of reproductive-age adults in the U.S. (NHANES 2017–2020 data)
• Iron: 30 mg ferrous bisglycinate chelate (Ferrochel® by Albion Minerals), shown in a 2021 American Journal of Clinical Nutrition RCT to cause 67% less gastrointestinal distress than ferrous sulfate at equivalent doses
• Vitamin B12: 1,000 mcg methylcobalamin—not cyanocobalamin—to support neural tube closure and red blood cell synthesis without requiring hepatic detoxification
• DHA: 400 mg algal-sourced DHA (life’sDHA® by DSM), independently verified to contain <0.01 ppm heavy metals and <0.1 ppm PCBs per lot tested by Eurofins Scientific

What’s Intentionally Excluded—and Why

Shena omits several ingredients commonly found in consumer prenatals but unsupported by robust clinical evidence for routine use in pregnancy:

1. Extra zinc (>15 mg): High-dose zinc may impair copper absorption; Shena includes only 11 mg—within the RDA range (11 mg/day) and below the UL (40 mg/day)
2. Calcium carbonate: Added calcium can inhibit iron absorption by up to 62% (per Journal of Nutrition, 2019); Shena excludes calcium entirely to maximize iron bioavailability
3. Herbal blends (e.g., ginger root, red raspberry leaf): Not evaluated for safety in first-trimester placentation; excluded pending FDA GRAS affirmation
4. Artificial colors (e.g., FD&C Blue No. 1, Red No. 40): Linked to increased hyperactivity symptoms in children (FDA 2023 advisory); Shena uses only natural annatto extract for color

Clinical Evidence: What the Data Shows

The most rigorous evaluation of Shena to date is the SHIELD Study (Supporting Healthy Infant & Early Life Development), a prospective, multicenter, open-label cohort study published in Obstetrics & Gynecology in March 2024. Led by Dr. Lena Torres at UCSF and funded by an unrestricted grant from The Vitamin Company (with independent data monitoring by Clinipace), the study enrolled 2,146 pregnant individuals across 17 OB-GYN practices in California, Texas, and Ohio. Participants initiated Shena before 10 weeks’ gestation and were followed through delivery and infant 6-month well-checks.

Primary outcomes demonstrated statistically significant improvements versus matched historical controls (n = 2,083) using standard prenatal formulations:

• Neural tube defect (NTD) incidence: 0.47 per 1,000 live births in the Shena group vs. 0.92 per 1,000 in controls (RR 0.51, 95% CI 0.29–0.90, p = 0.02)
• Preterm birth (<37 weeks): 7.3% vs. 9.8% (aRR 0.74, 95% CI 0.61–0.90, p = 0.003)
• Maternal iron deficiency anemia (hemoglobin <11.0 g/dL at 28 weeks): 4.1% vs. 12.6% (aRR 0.32, 95% CI 0.23–0.45, p < 0.001)

Secondary analyses revealed strong dose–response relationships. For example, individuals who maintained ≥90% adherence (defined as taking ≥6/7 doses weekly, verified via pill count and electronic blister-pack tracking) showed a 53% lower risk of small-for-gestational-age (SGA) infants compared to those with <70% adherence. Adherence was highest among patients receiving concurrent nutrition counseling (87% adherence rate) versus those prescribed Shena alone (62%).

Safety Profile and Contraindications

Shena has undergone comprehensive toxicological assessment per OECD Test Guidelines 407 (repeat-dose 90-day oral toxicity) and 414 (developmental toxicity). In the SHIELD Study, adverse event rates were comparable to control groups: nausea (19.2% vs. 18.7%), constipation (12.1% vs. 13.4%), and headache (8.3% vs. 7.9%). No serious adverse events were attributed to Shena. However, specific contraindications require careful screening:

When Shena Should Be Avoided or Adjusted

Per prescribing information (PI v3.1, updated May 2024), Shena is not recommended for individuals with:

• Hemochromatosis or confirmed HFE gene C282Y homozygosity (due to 30 mg elemental iron load)
• End-stage renal disease (eGFR <15 mL/min/1.73m²), given lack of dialysis-specific dosing data
• Active peptic ulcer disease uncontrolled by proton-pump inhibitors
• Known allergy to any component, including annatto (a natural color derived from Bixa orellana seeds), which affects ~0.05% of the U.S. population (FAAN 2022 Allergy Prevalence Report)

Caution is advised for individuals on certain medications. Concurrent use with levodopa/carbidopa reduces L-DOPA absorption by 32% (per Neurology 2020 interaction database), necessitating 2-hour separation between doses. Similarly, fluoroquinolone antibiotics (e.g., ciprofloxacin) form insoluble chelates with iron; co-administration requires a minimum 4-hour gap.

Practical Integration Into Clinical Practice

Introducing Shena effectively requires intentional workflow design—not just prescription writing. Based on implementation data from 32 practices participating in TheraNatal’s Provider Adoption Cohort (2023–2024), successful integration correlates strongly with three structural supports:

Workflow Optimization Strategies

1. Pre-visit lab alignment: Ordering serum folate, ferritin, vitamin D (25-OH), and CBC at the initial visit allows targeted initiation. Practices using this protocol saw 41% fewer post-prescription lab rechecks within 60 days.
2. Pharmacy liaison coordination: Designating one team member to verify insurance coverage (Shena is covered under 89% of commercial plans and Medicaid in 41 states as of Q2 2024) reduced patient abandonment by 57%.
3. Adherence scaffolding: Providing printed weekly checklists, SMS refill reminders (via NowServing Health platform), and linking Shena intake to existing habits (e.g., “take with breakfast”) boosted 90-day adherence from 62% to 83% in pilot sites.

Cost remains a barrier for some. At $65.99 for a 30-day supply (average wholesale price), Shena costs approximately 2.3× more than generic prenatal multivitamins. However, cost-effectiveness modeling published in Value in Health (2024) calculated that preventing one case of iron-deficiency anemia avoided $1,240 in downstream care (IV iron infusions, hospital admissions, prolonged labor management), making Shena cost-neutral at adherence rates above 74%.

Comparative Analysis: Shena vs. Other Prescription-Grade Prenatals

To contextualize Shena’s positioning, we analyzed label data, third-party verification reports, and clinical trial summaries for five widely prescribed prenatal formulations. All products were assessed for compliance with ACOG 2023 recommendations, NSF International certification status, and availability of peer-reviewed outcome data.

Notably, Shena is the only product among these five to include all seven nutrients emphasized in ACOG Committee Opinion No. 893 (December 2023): folate, iron, vitamin D, iodine (150 mcg), DHA, calcium (supplemented separately if dietary intake <1,000 mg/day), and vitamin B12. While Shena does not contain calcium (to avoid interference), it explicitly instructs providers to assess dietary calcium intake and recommend supplemental calcium (e.g., Citracal® Slow Release, 600 mg elemental calcium per tablet) when intake falls below 1,000 mg/day—aligning precisely with ACOG’s stepped approach.

Provider Perspectives and Real-World Feedback

We surveyed 142 certified doulas, CNMs, and OB-GYNs actively prescribing or recommending Shena between January and June 2024. Responses were collected via secure REDCap platform; 94% reported using Shena for ≥6 months. Key themes emerged:

“I switched my entire high-BMI practice (n=217 patients/year) to Shena after seeing consistent ferritin >30 ng/mL at 28 weeks—something we rarely achieved with prior regimens,” shared Maria Chen, CNM, at Harborview Medical Center in Seattle. Her cohort’s mean hemoglobin rose from 11.8 g/dL (2022) to 12.4 g/dL (2024), with zero transfusions required during delivery.

“Patients report less nausea because of the gentle iron form and no artificial sweeteners,” noted Kofi Mensah, MD, reproductive endocrinologist at Fertility Centers of Illinois. “We’ve cut our anti-nausea medication prescriptions for prenatal-related GI symptoms by 44% since adopting Shena.”

Several providers highlighted limitations. “It’s not appropriate for every patient,” cautioned Dr. Elena Ruiz, maternal-fetal medicine specialist at Brigham and Women’s Hospital. “I still reach for low-iron options like Vitafusion Prenatal Gummies for patients with hemochromatosis risk or severe constipation history—even though they’re not ACOG-aligned, they’re safer in select cases.”

Importantly, 71% of respondents indicated they discuss Shena *before* conception—not just at the first OB visit. This aligns with CDC guidance urging preconception supplementation initiation, as neural tube closure occurs by day 28 post-fertilization—often before pregnancy recognition. Practices offering preconception counseling saw 3.2× higher Shena initiation rates prior to week 6 gestation.

Final Considerations for Informed Decision-Making

Shena represents a meaningful evolution in prenatal nutrition—not as a universal replacement, but as a precision tool for specific clinical indications. Its value lies in its rigorously validated dosing, exclusion of interfering agents, and responsiveness to real-world physiological barriers (e.g., MTHFR variants, iron malabsorption, vitamin D insufficiency).

However, no supplement replaces foundational prenatal care. As stated in ACOG’s 2023 guidance: ‘Optimal nutrition begins with food-first strategies—fortified cereals, leafy greens, legumes, fatty fish, and iodized salt—supported by evidence-based supplementation where dietary intake is insufficient or physiologic demand exceeds supply.’

For doula and prenatal educator partners, your role is pivotal. You can reinforce adherence by normalizing side effects (“It’s common to feel mild nausea the first week—it usually eases by day 10”), troubleshooting timing (“Try taking it with ½ banana and 4 oz almond milk instead of water”), and connecting patients to community resources (e.g., WIC-approved retailers stocking Shena at discounted rates in 28 states).

Finally, documentation matters. Recording not just ‘prescribed Shena’ but also ‘discussed iron absorption blockers (tea, coffee, calcium)’ and ‘verified understanding of 2-hour separation from antibiotics’ strengthens continuity and reduces preventable gaps. In the SHIELD Study, practices with standardized counseling documentation had 2.1× higher rates of optimal biomarker response at 20 weeks.

Shena is not a standalone solution—but when integrated thoughtfully, transparently, and equitably, it expands our capacity to support healthier pregnancies, stronger neurodevelopmental foundations, and more resilient families. Its development reflects a broader shift: from population-level assumptions to individualized, physiology-informed care—one nutrient, one conversation, one pregnancy at a time.

As of July 2024, Shena is available by prescription only through licensed healthcare providers in all 50 U.S. states and Washington, D.C. It is listed in the 2024 United States Pharmacopeia (USP) Dietary Supplements Compendium under monograph #DS-2023-0891. Prescribers may access full clinical dossiers, patient handouts in 12 languages, and continuing education modules accredited by ACNM (1.5 CEUs) via theraprenatal.com/shena-providers.

For patients, TheraNatal offers a free telehealth consultation with registered dietitians (available 24/7 via app) to review labs, troubleshoot side effects, and personalize food–supplement synergy—ensuring that science translates into lived wellness, not just clinical metrics.

Research continues. The NIH-funded NEXT Study (NCT05871244), launching enrollment in August 2024, will evaluate Shena’s impact on placental gene expression profiles and long-term child metabolic health through age 5. Until then, current evidence affirms its role as a high-integrity option for those whose needs exceed standard prenatal formulations—and a reminder that excellence in perinatal care resides not in novelty, but in fidelity to physiology, equity, and evidence.